The US company, Constellation Pharmaceuticals, has announced that it has initiated a new Phase I trial of its proprietary drug, CPI-0610, for the treatment of myeloma patients who have relapsed after at least one prior line of treatment. CPI-0610 is a small molecule that inhibits bromodomain and extra-terminal (BET) proteins which are involved in chromatin structure and function. Bromodomain inhibitors have attracted attention as potential treatments for a range of different cancers and the trial is an expansion of an ongoing study of CPI-0610 in lymphoma.

Read the full article